- Home
- AVD vs GLSI Comparison
AVD vs GLSI Comparison
Compare AVD & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- GLSI
- Stock Information
- Founded
- AVD 1969
- GLSI 2006
- Country
- AVD United States
- GLSI United States
- Employees
- AVD N/A
- GLSI N/A
- Industry
- AVD Agricultural Chemicals
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- GLSI Health Care
- Exchange
- AVD Nasdaq
- GLSI Nasdaq
- Market Cap
- AVD 158.9M
- GLSI 149.5M
- IPO Year
- AVD N/A
- GLSI 2020
- Fundamental
- Price
- AVD $5.61
- GLSI $11.23
- Analyst Decision
- AVD Strong Buy
- GLSI Strong Buy
- Analyst Count
- AVD 1
- GLSI 1
- Target Price
- AVD $12.00
- GLSI $39.00
- AVG Volume (30 Days)
- AVD 165.0K
- GLSI 55.9K
- Earning Date
- AVD 11-10-2025
- GLSI 08-14-2025
- Dividend Yield
- AVD N/A
- GLSI N/A
- EPS Growth
- AVD N/A
- GLSI N/A
- EPS
- AVD N/A
- GLSI N/A
- Revenue
- AVD $529,067,000.00
- GLSI N/A
- Revenue This Year
- AVD N/A
- GLSI N/A
- Revenue Next Year
- AVD $3.54
- GLSI N/A
- P/E Ratio
- AVD N/A
- GLSI N/A
- Revenue Growth
- AVD N/A
- GLSI N/A
- 52 Week Low
- AVD $3.28
- GLSI $8.06
- 52 Week High
- AVD $6.68
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- AVD 62.42
- GLSI 46.72
- Support Level
- AVD $5.24
- GLSI $11.12
- Resistance Level
- AVD $5.84
- GLSI $13.00
- Average True Range (ATR)
- AVD 0.25
- GLSI 0.63
- MACD
- AVD -0.03
- GLSI -0.06
- Stochastic Oscillator
- AVD 70.13
- GLSI 26.56
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.